Metastatic Solid Tumors Articles & Analysis: Older
7 articles found
Sialic acid proteins are a special type of glycoproteins, characterized by the presence of sialic acid at the end of the sugar chain. Sialic acid is a biologically important sugar molecule that plays a crucial role in many intercellular interactions, including cell recognition, adhesion and signal transduction. Therefore, the detection of sialic acid proteins holds significant value in disease ...
Brain tumors can be broadly categorized into primary and secondary (or metastatic) tumors. Primary tumors originate in the brain1, while secondary tumors spread from other body parts. Treatment options traditionally include surgery, radiation therapy, and chemotherapy. However, these approaches can be invasive and have severe side effects. The battle against brain tumors is being ...
ZAP Surgical Systems, Inc. today announced it has received CE mark clearance to the new EU MDR for its ZAP-X® Gyroscopic Radiosurgery® platform. The CE mark makes it possible for healthcare providers to begin treating patients with the ZAP-X system in the European Union. For select indications including many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) is proven ...
CURRENT STANDARD OF CARE FOR BRAIN TUMORS The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started outside of the brain—is resection. After surgery, a follow-up treatment, also referred to as adjuvant treatment, is often recommended to help eliminate ...
ABSTRACT Patients with brain tumors face enormous challenges after diagnosis. Many of these challenges are amplified by issues related to access to care.1‒4 Studies suggest that patients with cancer who live farther from radiation treatment centers have poorer clinical outcomes. In addition, minorities are more likely to perceive longer travel distances as a barrier, which may cause them ...
ZAP Surgical Systems, Inc. today announced it has received Shonin approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for its ZAP-X® Gyroscopic Radiosurgery® platform. As part of the approval, ZAP-X is now cleared for clinical use in Japan. To facilitate a robust market introduction effort, ZAP also announced a partnership with MC Medical Inc. to lead Japanese ...
ZAP Surgical Systems, Inc. today announced ZAP-X® Gyroscopic Radiosurgery® patient treatments have commenced at MedStar Georgetown Cancer Institute at MedStar Southern Maryland Hospital Center in Clinton, MD. For many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) has proven to be an effective treatment with outcomes equivalent to invasive surgical procedures. ...